Perpetual Ltd’s BioMarin Pharmaceuticals BMRN Stock Holding History

Perpetual Ltd’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,997	Closed	-$734K	–	426
2026 Q1	$734K	Sell	12,997 -12,624	-49%	-$736K	0.01%	257
2025 Q4	$1.52M	Buy	25,621 +20,747	+426%	+$1.13M	0.02%	203
2025 Q3	$264K	Sell	4,874 -9,106	-65%	-$521K	﹤0.01%	373
2025 Q2	$768K	Buy	+13,980	New	+$823K	0.01%	270
2025 Q1	–	Sell	-3,501	Closed	-$230K	–	414
2024 Q4	$230K	Buy	+3,501	New	+$235K	﹤0.01%	396

Other funds holding BMRN

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Covea Finance Paris, France $3.17B AUM 35.01% 1-Year Est. Return

AWM

Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

Perpetual Ltd's BMRN Position: Q2 2026 in Review

Perpetual Ltd sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 12,997 shares — an estimated $734K sold.

Perpetual Ltd first reported a position in BMRN in Q4 2024 and held it in 5 quarters. The position peaked at $1.52M in Q4 2025. 143 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Perpetual Ltd reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Perpetual Ltd sold 12,997 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $734K.
Perpetual Ltd first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 5 quarters.
Perpetual Ltd's BioMarin Pharmaceuticals position peaked at $1.52M in Q4 2025.
143 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Perpetual Ltd's 13F filing for Q2 2026, filed 15 Jul 2026.